|
|
|
|
As Hepatitis B virus (HBV) clinical trials advance, refining therapeutic endpoints and integrating novel treatment strategies are essential to transforming Hepatitis B management. Explore how Asia-Pacific is leading the global clinical trial landscape for Hepatitis B, the emerging biomarkers that are improving the precision of disease monitoring and treatment response assessment, and more.
|
|
|
|
|
Hepatitis B is a major global health challenge leading to severe liver complications, including cirrhosis and cancer. While current antiviral treatments effectively suppress viral replication and slow disease progression, they do not offer a functional cure. However, emerging therapies and ongoing clinical trials are paving the way for more advanced treatment strategies.
|
|
|
|
|
Southeast Asia has emerged as a pivotal region for vaccine clinical trials, driven by rapid recruitment, cost efficiency, and robust immunization infrastructure. The region's significance has surged in the post-Covid-19 era with the Asia-Pacific leading in prophylactic vaccine trials with Southeast Asia's large, vaccine-naïve population and the prevalence of communicable diseases presenting unique opportunities.
|
|
|
|
|
With over 1,500 TNBC-focused clinical trials since 2019, research efforts into Triple-negative breast cancer (TNBC) treatments are accelerating despite challenges such as drug resistance. Emerging therapies and an evolving treatment landscape that integrates biomarker-driven strategies are offering promising advancements.
|
|
|
|
|
This case study highlights a successful Phase IIb clinical trial conducted by an Indian biotech company evaluating a novel treatment for Locally Advanced or Metastatic Breast Cancer. Novotech played a pivotal role in overcoming the complexities of this oncology trial, managing patient recruitment and multi-site coordination across three locations.
|
|
|
|
|
This webinar delves into solutions for conducting clinical trials in today’s unpredictable global landscape. Our panel will equip sponsors, researchers, and stakeholders with the tools to enhance trial resilience and ensure continuity in uncertain environments.
|
|
|
